Mark Nelson

28.5k total citations · 2 hit papers
418 papers, 17.5k citations indexed

About

Mark Nelson is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Mark Nelson has authored 418 papers receiving a total of 17.5k indexed citations (citations by other indexed papers that have themselves been cited), including 223 papers in Infectious Diseases, 143 papers in Virology and 131 papers in Epidemiology. Recurrent topics in Mark Nelson's work include HIV/AIDS drug development and treatment (162 papers), HIV Research and Treatment (142 papers) and HIV/AIDS Research and Interventions (100 papers). Mark Nelson is often cited by papers focused on HIV/AIDS drug development and treatment (162 papers), HIV Research and Treatment (142 papers) and HIV/AIDS Research and Interventions (100 papers). Mark Nelson collaborates with scholars based in United Kingdom, United States and Germany. Mark Nelson's co-authors include Brian Gazzard, Mark Bower, Justin Stebbing, Michael H. Goldbaum, Nathan Clumeck, Sundhiya Mandalia, Mark Sulkowski, Eduardo Lissen, Julio Montaner and Francesca J. Torriani and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Mark Nelson

406 papers receiving 17.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

2006 3.5k citations Mark Nelson et al. profile →
Detection of blood vessels in retinal images using two-dimensional matched filters

1989 1.2k citations Subhasis Chaudhuri, Mark Nelson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Nelson United Kingdom	60	7.8k	6.2k	5.1k	3.6k	2.9k	418	17.5k
James J. Goedert United States	75	7.6k 1.0×	5.9k 1.0×	4.3k 0.8×	7.4k 2.0×	5.7k 2.0×	326	27.0k
Richard A. Kaslow United States	61	6.8k 0.9×	6.6k 1.1×	3.6k 0.7×	7.5k 2.1×	1.1k 0.4×	221	19.8k
Massimo Galli Italy	55	3.3k 0.4×	5.4k 0.9×	1.4k 0.3×	2.7k 0.7×	1.2k 0.4×	500	13.0k
Fu‐Sheng Wang China	54	5.5k 0.7×	6.9k 1.1×	3.6k 0.7×	714 0.2×	3.0k 1.1×	310	19.9k
Geneviève Chêne France	64	4.7k 0.6×	7.6k 1.2×	1.2k 0.2×	5.2k 1.4×	1.3k 0.5×	425	15.9k
Peter Simmonds United Kingdom	102	17.8k 2.3×	15.0k 2.4×	15.8k 3.1×	5.0k 1.4×	2.1k 0.7×	529	38.6k
David Venzon United States	81	6.2k 0.8×	2.5k 0.4×	363 0.1×	4.4k 1.2×	5.8k 2.0×	402	21.3k
Eric A. Engels United States	81	7.8k 1.0×	2.7k 0.4×	1.1k 0.2×	862 0.2×	12.7k 4.4×	386	24.8k
Raymond T. Chung United States	79	12.9k 1.6×	2.6k 0.4×	13.5k 2.6×	1.4k 0.4×	1.5k 0.5×	431	23.1k
Dominique Costagliola France	69	5.6k 0.7×	9.0k 1.4×	1.0k 0.2×	7.3k 2.0×	2.7k 0.9×	450	17.8k

Countries citing papers authored by Mark Nelson

Since Specialization

Citations

This map shows the geographic impact of Mark Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Nelson more than expected).

Fields of papers citing papers by Mark Nelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Nelson. The network helps show where Mark Nelson may publish in the future.

Co-authorship network of co-authors of Mark Nelson

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Nelson. A scholar is included among the top collaborators of Mark Nelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Nelson. Mark Nelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Beilei, Muideen T. Olaiya, Dominique A. Cadilhac, et al.. (2025). Quality indicators for lifestyle or behavioural management for the primary prevention of cardiovascular disease in primary care: a systematic review. BJGP Open. 9(4). BJGPO.2025.0018–BJGPO.2025.0018. 1 indexed citations

Fravel, Michelle A., Michael E. Ernst, Robyn L. Woods, et al.. (2024). Effects of statins on kidney function in older adults. Journal of the American Geriatrics Society. 73(4). 1082–1093. 1 indexed citations

Wolfe, Rory, James B. Wetmore, Anne M. Murray, et al.. (2024). Classification of chronic kidney disease in older Australian adults by the CKD‐EPI 2009 and 2021 equations: secondary analysis of ASPREE study data. The Medical Journal of Australia. 222(2). 74–81.

Vera, Jaime H., Margherita Bracchi, Jasmini Alagaratnam, et al.. (2019). Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART. Brain Sciences. 9(8). 195–195. 14 indexed citations

Nelson, Mark, Rafael Rubio, Adriano Lazzarin, et al.. (2017). Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. Journal of Interferon & Cytokine Research. 37(3). 103–111. 13 indexed citations

José, Sophie, Killian Quinn, Teresa Hill, et al.. (2014). Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy. AIDS. 28(9). 1333–1339. 8 indexed citations

Behrens, Georg M. N., Bart Rijnders, Mark Nelson, et al.. (2014). Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis. AIDS Patient Care and STDs. 28(4). 168–175. 23 indexed citations

Singh, Gurmit, Samreen Ijaz, Neesha Rockwood, et al.. (2011). Chronic Hepatitis E as a cause for cryptogenic cirrhosis in HIV. Journal of Infection. 66(1). 103–106. 67 indexed citations

Kikuchi, Luciana, Pablo Barreiro, Mark Nelson, et al.. (2010). 1065 IMPACT OF SCREENING FOR HEPATOCELLULAR CARCINOMA (HCC) IN HIV/HCV-COINFECTED PATIENTS ON STAGING, THERAPY AND SURVIVAL. Journal of Hepatology. 52. S412–S412. 1 indexed citations

10.

Nelson, Mark, Martin Fisher, Juan González‐García, et al.. (2010). Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus Optimized Background Therapy in the MOTIVATE 1 and 2 Trials. HIV Clinical Trials. 11(3). 145–155. 1 indexed citations

11.

Westrop, Samantha J., Jeffrey Pido-Lopez, Mark Nelson, et al.. (2009). Transient Nature of Long-Term Nonprogression and Broad Virus-Specific Proliferative T-Cell Responses with Sustained Thymic Output in HIV-1 Controllers. PLoS ONE. 4(5). e5474–e5474. 20 indexed citations

12.

Powles, Thomas, David Robinson, Justin Stebbing, et al.. (2008). Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection. Journal of Clinical Oncology. 27(6). 884–890. 269 indexed citations

13.

Boffito, Marta, Laura Dickinson, David Back, et al.. (2006). Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir and Atazanavir When Combined Once Daily in HIV Type 1-Infected Individuals Administered Different Atazanavir Doses. AIDS Research and Human Retroviruses. 22(8). 749–756. 11 indexed citations

14.

Qiao, Li, Amelia Grover, Jiyun Yu, et al.. (2005). Simultaneous Targeting of CD3 on T Cells and CD40 on B or Dendritic Cells Augments the Antitumor Reactivity of Tumor-Primed Lymph Node Cells. The Journal of Immunology. 175(3). 1424–1432. 34 indexed citations

15.

Thomas, Claire, Mark Nelson, & Justin Stebbing. (2003). HIV and Hepatitis B: A Review. AIDS Patient Care and STDs. 17(12). 623–633. 3 indexed citations

16.

Portsmouth, Simon, et al.. (2002). The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma. AIDS. 16(17). 2344–2347. 18 indexed citations

17.

Bower, Mark, et al.. (1999). HAART PROLONGS TIME TO TREATMENT FAILURE (TTF) IN KAPOSI'S SARCOMA (KS).. JAIDS Journal of Acquired Immune Deficiency Syndromes. 21(1). A24–A24. 11 indexed citations

18.

Nelson, Mark, et al.. (1996). Mycobacterium kansasii: its presentation, treatment and outcome in HIV infected patients.. Journal of Clinical Pathology. 49(10). 821–823. 14 indexed citations

19.

Nelson, Mark. (1992). File verification using CRC. 17(5). 64–67. 4 indexed citations

20.

Goldbaum, Michael H., et al.. (1989). Image Understanding for Automated Retinal Diagnosis.. PubMed Central. 756–760. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact